

10-1-2011

Advanced glycation end products accelerate ischemia/reperfusion injury through receptor of advanced end product/nitrative thioredoxin inactivation in cardiac microvascular endothelial cells.

Yi Liu

Department of Cardiology, Xijing Hospital, Fourth Military Medical University, 15 Changle West Road, Xi'an 710032, China

Yanzhuo Ma

Department of Cardiology, Xijing Hospital, Fourth Military Medical University, 15 Changle West Road, Xi'an 710032, China

Rutao Wang

Department of Cardiology, Xijing Hospital, Fourth Military Medical University, 15 Changle West Road, Xi'an 710032, China

Chenhai Xia

Department of Cardiology, Xijing Hospital, Fourth Military Medical University, 15 Changle West Road, Xi'an 710032, China

Rongqing Zhang

Department of Cardiology, Xijing Hospital, Fourth Military Medical University, 15 Changle West Road, Xi'an 710032, China

Recommended Citation

Liu, Yi; Ma, Yanzhuo; Wang, Rutao; Xia, Chenhai; Zhang, Rongqing; Lian, Kun; Luan, Ronghua; Sun, Lu; Yang, Lu; Lau, Wayne B; Wang, Haichang; and Tao, Ling, "Advanced glycation end products accelerate ischemia/reperfusion injury through receptor of advanced end product/nitrative thioredoxin inactivation in cardiac microvascular endothelial cells." (2011). *Department of Emergency Medicine Faculty Papers*. Paper 10.

<http://jdc.jefferson.edu/emfp/10>

See next page for additional authors

Let us know how access to this document benefits you

Follow this and additional works at: <http://jdc.jefferson.edu/emfp>

 Part of the [Alternative and Complementary Medicine Commons](#), [Cardiology Commons](#), and the [Emergency Medicine Commons](#)

Authors

Yi Liu, Yanzhuo Ma, Rutao Wang, Chenhai Xia, Rongqing Zhang, Kun Lian, Ronghua Luan, Lu Sun, Lu Yang, Wayne B Lau, Haichang Wang, and Ling Tao

Advanced Glycation End Products Accelerate Ischemia/Reperfusion Injury Through Receptor of Advanced End Product/Nitrative Thioredoxin Inactivation in Cardiac Microvascular Endothelial Cells

Yi Liu,¹ Yanzhuo Ma,¹ Rutao Wang,¹ Chenhai Xia,¹ Rongqing Zhang,¹ Kun Lian,¹ Ronghua Luan,¹ Lu Sun,¹ Lu Yang,¹ Wayne B. Lau,² Haichang Wang,¹ and Ling Tao¹

Abstract

The advanced glycation end products (AGEs) are associated with increased cardiac endothelial injury. However, no causative link has been established between increased AGEs and enhanced endothelial injury after ischemia/reperfusion. More importantly, the molecular mechanisms by which AGEs may increase endothelial injury remain unknown. Adult rat cardiac microvascular endothelial cells (CMECs) were isolated and incubated with AGE-modified bovine serum albumin (BSA) or BSA. After AGE-BSA or BSA preculture, CMECs were subjected to simulated ischemia (SI)/reperfusion (R). AGE-BSA increased SI/R injury as evidenced by enhanced lactate dehydrogenase release and caspase-3 activity. Moreover, AGE-BSA significantly increased SI/R-induced oxidative/nitrative stress in CMECs (as measured by increased inducible nitric oxide synthase expression, total nitric oxide production, superoxide generation, and peroxynitrite formation) and increased SI/R-induced nitrative inactivation of thioredoxin-1 (Trx-1), an essential cytoprotective molecule. Supplementation of EUK134 (peroxynitrite decomposition catalyst), human Trx-1, or soluble receptor of advanced end product (sRAGE) (a RAGE decoy) in AGE-BSA precultured cells attenuated SI/R-induced oxidative/nitrative stress, reduced SI/R-induced Trx-1 nitration, preserved Trx-1 activity, and reduced SI/R injury. Our results demonstrated that AGEs may increase SI/R-induced endothelial injury by increasing oxidative/nitrative injury and subsequent nitrative inactivation of Trx-1. Interventions blocking RAGE signaling or restoring Trx activity may be novel therapies to mitigate endothelial ischemia/reperfusion injury in the diabetic population. *Antioxid. Redox Signal.* 15, 1769–1778.

Introduction

DIABETES MELLITUS is a major risk factor for cardiovascular disease, with vascular complications as the leading etiology of morbidity and mortality in the diabetic population (13). Despite interventional technique advances, the diabetic condition portends an adverse outcome after revascularization (21). Further, diabetic rats subjected to ischemia/reperfusion (I/R) injury manifest increased apoptosis of cardiac microvascular endothelial cells (CMECs) (33). However, the molecular mechanisms by which the diabetic state sensitizes CMECs to I/R injury are unclear.

Many hyperglycemia-induced metabolic derangements and abnormalities have been identified as being responsible

for endothelial cell dysfunction. Among them, the advanced glycation end products (AGEs), and their receptor (RAGE), have been strongly implicated in the pathogenesis of diabetic vascular complications (24). It is well known that the interaction of AGEs with RAGE increases the intracellular reactive oxygen species (ROS) generation, subsequently inducing apoptotic cell death and injury in endothelial cells (3, 7, 19). Recent evidence demonstrates that nitric oxide (NO) reactive nitrogen species such as peroxynitrite (ONOO⁻), a critical contributor of protein nitrative modification and cell injury, play a crucial role in I/R-induced cardiomyocyte injury (26). However, whether AGEs could cause cardiac cell injury by nitrative stress and induce subsequent protein nitrative modification remains incompletely understood. More

¹Department of Cardiology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.

²Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania.

importantly, specific intracellular molecules nitratively modified and thereby contributive to increased endothelial damage in the diabetic patient is completely unknown.

Ubiquitously expressed in living cells, thioredoxin-1 (Trx-1) is a small protein with many protective biological functions. Trx-1 not only exerts cytoprotective functions against oxidative stress but also regulates cell survival signaling pathways (15, 25, 38). In addition to its upregulated or downregulated expression at the gene level, Trx activity is regulated by posttranslational modification (25). Previously, we demonstrated for the first time that Trx-1 can be modified at the tyrosine residue by nitration, resulting in loss of its cardioprotective action (28). In a recent study (37), we demonstrated that nitrative inactivation of Trx-1 increases vulnerability of diabetic hearts to I/R injury. However, the upstream molecules and mechanisms causing increased nitrative Trx inactivation in diabetic endothelial cells remain unidentified.

Therefore, the aims of the present study were (i) to determine whether AGEs could exacerbate CMECs I/R injury; (ii) to examine whether AGEs increase nitrative stress and subsequent nitrative Trx-1 inactivation; and (iii) to determine any cause-effect relationship between AGE-RAGE-induced nitrative Trx inactivation and increased I/R injury in CMECs.

Materials and Methods

Preparation of AGE proteins

AGE-bovine serum albumin (BSA) was prepared as previously described (35). Briefly, BSA (50 mg/ml) was incubated under sterile conditions with 0.5 M D-glucose in 100 mM sodium phosphate buffer (phosphate-buffered saline [PBS], pH 7.4) at 37°C for 9 weeks. Unincorporated sugars were removed by dialysis against PBS. Control BSA was incubated under the same conditions, in the absence of reducing sugars. AGE content was determined spectrofluorometrically (360 nm excitation, and 450 nm emission) and expressed as the

percentage of relative fluorescence compared with control BSA. Preparations were tested for endotoxin using Endospecy ES-20S system (Seikagaku Co.); no endotoxin was detectable.

CMECs culture and identification

CMECs were isolated as previously described (17), with minor modifications. Briefly, male Wistar rats (200–250 g) were anesthetized with ether, and the heart was rapidly excised and rinsed with PBS supplemented with heparin. After rinsing, the right ventricle, atria, and valvular tissues were removed, and the remaining left ventricle was immersed in 75% ethanol for 20–30 s to devitalize epicardial mesothelial cells and endocardial endothelial cells. About one-third of the outer free ventricular wall was dissected to remove epicardial arteries. The remaining tissue was then minced in PBS and incubated in 0.2% collagenase (type II; Sigma Aldrich) for 10 min, followed by 0.2% trypsin (Sigma Aldrich) for another 6 min at 37°C in a water bath. Dissociated cells were filtered through a 100 mm mesh filter. After centrifugation of the dissociated cells at 1000 rpm for 10 min, cells were re-suspended in Dulbecco's minimum essential medium (DMEM) (Invitrogen Gibco) supplemented with 20% (v/v) fetal calf serum and heparin (20 U/ml) and plated on laminin (10 µg/ml)-coated dishes. Primary cultures of CMECs were positively identified by two endothelial cell markers: factor VIII-related antigen and uptake of acetylated low-density lipoprotein (Kalen Biomed). Differential uptake of acetylated low-density lipoprotein, determined by fluorescence-activated cell sorting, indicated that the cultures contained >90% endothelial cells (Fig. 1).

Experimental protocol and simulated ischemia/reperfusion

Passage 2 CMECs were used in the study. After 24 h synchronization, cells were washed with PBS; and nonadherent




FIG. 1. Characterization of cardiac microvascular endothelial cells (CMECs). (A) CMECs monolayer presents cobble stone appearance by phase-contrast microscopy; expression of factor VIII by immunohistochemistry (B1: negative control, B2: factor VIII positive); uptake of acetylated low-density lipoprotein by immunofluorescence: (C1: accumulation of acetylated low-density lipoprotein, C2: 4, 6-diamidino-2-phenylindole staining indicates nuclei, C3: merge of C1 and C2). Original magnification: $\times 400$ (A, B), $\times 1000$ (C).

cells were removed from the culturing system and were randomly assigned to one of the following treatments: BSA (100 $\mu\text{g}/\text{ml}$ as control), AGE-BSA (100 $\mu\text{g}/\text{ml}$), AGE-BSA + EUK134 (7 μM , a peroxynitrite decomposition catalyst; Cayman Chemical), AGE-BSA + human Trx-1 (hTrx-1) (1 $\mu\text{g}/\text{ml}$; Sigma), or AGE-BSA + sRAGE (4 $\mu\text{g}/\text{ml}$, a RAGE decoy; Adipobioscience). After 48 h incubation, cells were subjected to either sham simulated ischemia/reperfusion (SI/R, 10 h of normoxia/normal-glucose environment) or SI/R (4 h hypoxia-hypoglycemic environment plus 6 h normoxia/normal glucose environment) as previously described (36). Briefly, the oxygen-glucose deprivation injury occurred by placing cells in a hypoxic environment (1% $\text{O}_2/5\%$ $\text{CO}_2/94\%$ N_2) maintained by an incubator in the presence of glucose-free DMEM for 4 h, at which time the medium was exchanged with oxygenated and normal glucose DMEM in an incubator at 37°C to simulate the reperfusion condition for 6 h.

Assessment of SI/R-induced CMECs injury

To determine CMECs death, lactate dehydrogenase (LDH) release was determined by an enzyme activity assay kit (Nanjing Institute of Jiancheng Bioengineering). Caspase-3 activity was determined by caspase-3 activity assay kit (Chemicon). Caspase-3 activity was expressed as nmol pNA/h/mg protein.

Quantification of superoxide production, cellular nitrotyrosine content

Superoxide production, an index of oxidative stress, in viable CMECs was measured by lucigenin-enhanced chemiluminescence as previously described (17) and expressed as relative light units per second per milligram protein. CMECs nitrotyrosine content, an index of protein nitration and nitrate stress, was determined as described in our previous study (27).

Total NO assay

The supernatant fluid of CMECs was harvested, and NO concentrations were measured with Griess reagent using an assay kit (Beyotime Company). The amount of total cellular protein in the respective wells was determined by Lowry's method after lysis with a buffer containing 0.1% of sodium dodecyl sulfate in 10 mM Tris, pH 7.4. Total nitrite accumulated in each well was defined as $\mu\text{M}/\text{mg}$ of protein in the corresponding well.

Western blot analysis for Trx-1, inducible nitric oxide synthase, RAGE, and gp91phox

CMECs were lysed in lysis buffer and centrifuged; the supernatant was utilized to determine Trx expression. Equal protein amounts were electrophoresed on a 14% sodium dodecyl sulfate-polyacrylamide gel and then electrophoretically transferred to a polyvinylidene difluoride membrane (Millipore). After blocking with 5% skim milk in Tris-buffered saline containing 0.05% Tween 20 at room temperature for 1 h, the membrane was incubated with a monoclonal anti-murine Trx antibody (Redox Bioscience), an anti-murine RAGE antibody (Santa Cruz), an anti-murine gp91phox (Santa Cruz) antibody, or an anti-murine inducible nitric oxide synthase

(iNOS) antibody (Cell Signaling) and then with the HRP linked IgG (Cell Signaling). The blot was developed with an ECL-Plus chemiluminescence reagent kit (Amersham) and visualized with UVP Bio-Imaging Systems. Blot densities were analyzed with Vision Works LS Acquisition and Analysis Software.

Trx activity assay

Trx activity was determined *via* the insulin disulfide reduction assay (11). Briefly, 40 μg of cellular protein extracts were preincubated at 37°C for 15 min with 2 ml activation buffer (100 mM HEPES, 2 mM ethylenediaminetetraacetic acid, 1 mg/ml BSA, and 2 mM DL-Dithiothreitol) to reduce Trx. After addition of 20 μL reaction buffer (100 mM HEPES, 2.0 mM ethylenediaminetetraacetic acid, 0.2 mM NADPH, and 140 mM insulin), the reaction was initiated by addition of mammalian Trx reductase (1 ml, 15 mU; Sigma) or water to controls. After incubation for 30 min at 37°C, the reaction was terminated by 125 μL stopping solution (0.2 M Tris-CL, 10 M guanidine-HCl, and 1.7 mM 3-carboxy-4-nitrophenyl disulfide, DTNB), followed by absorption measurement (412 nm). Trx-1 activity was expressed as oxidized NADPH $\mu\text{mol}/\text{min}/\text{mg}$ of protein.

Detection of Trx-1 nitration

CMECs were homogenized with lysis buffer. Endogenous Trx-1 was immunoprecipitated with a monoclonal anti-murine Trx-1 antibody (Redox Bioscience). After sample separation, Trx-1 nitration was detected with a monoclonal antibody (Upstate) against nitrotyrosine. The blot was developed with an ECL-Plus chemiluminescence reagent kit (Amersham) and visualized with UVP Bio-Imaging Systems. Blot densities were analyzed with Vision Works LS Acquisition and Analysis Software.

Statistical analysis

All values in the text and figures are presented as means \pm standard error. All data (except Western blot density) were subjected to analysis of variance followed by Bonferroni correction for *post hoc* t test. Western blot densities were analyzed with the Kruskal-Wallis test followed by Dunn's *post hoc* test. Probabilities of 0.05 or less were considered to be statistically significant.

Results

AGE-BSA increases the SI/R injury in CMECs

To investigate the role of AGE-BSA on SI/R-induced injury in CMECs, we examined the effects of AGE-BSA on the SI/R-induced caspase-3 activity and LDH release in CMECs. SI/R induced a significant LDH release (Fig. 2A) and caspase-3 activation (Fig. 2B). Compared with cells precultured in BSA, cells precultured in AGE-BSA had increased SI/R-induced LDH release (Fig. 2A) and caspase-3 activity (Fig. 2B).

AGE-BSA promotes the SI/R-induced oxidative/nitrative stress in CMECs

To determine whether AGE-BSA exacerbates SI/R-induced oxidative/nitrative stress, we examined iNOS protein




FIG. 2. Effects of AGE-BSA preculture on subsequent simulated ischemia/reperfusion-induced LDH release and caspase-3 activity in CMECs. Advanced glycation end products–modified bovine serum albumin (AGE-BSA) increases the simulated ischemia/reperfusion (SI/R)-induced lactate dehydrogenase (LDH) release (A) and caspase-3 activity (B) in CMECs. $n = 8–12$ wells/group. # $p < 0.05$, ## $p < 0.01$ versus Control+Sham group, ** $p < 0.05$ versus AGE-BSA+Sham group.

expression and total NO production. It has been documented that iNOS activation can result in excessive reactive nitrogen species production (31). Elevated production of peroxynitrite increases protein modification at the tyrosine residue, increasing nitrotyrosine formation (19). Not only did SI/R increase oxidative stress in CMECs, evidenced by enhanced superoxide generation (Fig. 3A), but also it increased nitritative stress as well, evidenced by greater iNOS expression (Fig. 3B), total NO production (Fig. 3C), and nitrotyrosine production (Fig. 3D). Further, AGE-BSA additionally amplified SI/R-induced superoxide generation (Fig. 3A), iNOS expression (Fig. 3B), total NO production (Fig. 3C), and nitrotyrosine production (Fig. 3D) in CMECs.

AGE-BSA promotes SI/R-induced Trx-1 inactivation and nitration

Recently, we demonstrated that nitritative Trx-1 inactivation plays a causative role in myocardial I/R injury (12). Having demonstrated that AGE-BSA promoted SI/R-induced nitritative stress in CMECs, we tested a hypothesis that AGE-BSA promotes SI/R-injury *via* nitritative Trx-1 inactivation. As

shown in Figure 4A, SI/R decreased Trx-1 activity in both control and AGE-BSA group, compared with sham. This observed decrease in Trx-1 activity occurred despite increased expression of Trx-1 protein in both groups (Fig. 4A, B). Further, AGE-BSA additionally amplified SI/R-induced Trx-1 inactivation (but had no effect on Trx-1 expression in sham or SI/R conditions). Moreover, AGE-BSA further enhanced SI/R-induced Trx nitration (Fig. 4C). These studies demonstrated the promotion of Trx-1 inactivation by AGE-BSA possibly *via* posttranslational modification, without alteration of Trx-1 expression.

Preventing Trx-1 nitration or treatment with exogenous Trx-1 attenuates SI/R injury and RAGE expression in cells precultured with AGE-BSA

In the present study, we demonstrated that AGE-BSA exacerbated SI/R injury, increasing SI/R-induced nitritative stress and nitritative Trx-1 inactivation in CMECs. However, whether AGE-BSA-induced increased Trx nitritative inactivation is causatively related to increased SI/R-injury in CMECs remains unknown. We performed the following study to gain more insight. During the 48 h AGE-BSA incubation period, CMECs were treated with EUK134 (a peroxynitrite decomposition catalyst) or recombinant hTrx-1 and then subjected to SI/R. As summarized in Figure 5, treatment with EUK134 or hTrx-1 significantly attenuated SI/R-induced injury, as evidenced by mitigated LDH release (Fig. 5A) and caspase-3 activity (Fig. 5B). EUK134 or hTrx-1 dramatically attenuated both nitrotyrosine content (Fig. 5C) and Trx nitration (Fig. 5D) and recovered Trx-1 activity (Fig. 5E). Interestingly, we unexpectedly found that, compared with vehicle, EUK134 or hTrx-1 significantly decreased RAGE expression (Fig. 5F), suggesting that nitritative Trx-1 inactivation promotes RAGE expression.

Blockade of RAGE attenuated SI/R injury in cells cultured with AGE-BSA

We performed an additional experiment to provide more evidence supporting the central hypothesis that AGE-RAGE stimulated superoxide/NO/peroxynitrite overproduction is the upstream mechanism inducing increased nitritative Trx-1 inactivation in the diabetic condition. During the 48 h AGE-BSA incubation period, CMECs were treated with sRAGE (a RAGE decoy) and then subjected to SI/R. Caspase-3 activity, LDH release, Trx-1 nitration, Trx-1 activity, and gp91phox (the major component of NADPH oxidase) were assessed. sRAGE recovered Trx-1 activity (Fig. 6D), while attenuating CMECs LDH release (Fig. 6A), caspase-3 activity (Fig. 6B), Trx-1 nitration (Fig. 6C), and gp91phox expression (Fig. 6E).

Discussion

We have made several important observations in the present investigation. First, we demonstrated for the first time that AGE-BSA promotes SI/R-induced injury in CMECs. Second, we further demonstrated nitritative Trx inactivation as an exacerbating factor to SI/R-induced injury in AGE-BSA pretreated CMECs, a novel mechanism by which AGEs cause endothelial injury. Third, we provided the first evidence that RAGE acts as a modulator of both nitritative stress and sub-




FIG. 3. Effects of AGE-BSA preculture or subsequent simulated ischemia/reperfusion-induced oxidative/nitritive stress in CMECs. AGE-BSA promotes the SI/R-induced superoxide generation (A), inducible nitric oxide synthase (iNOS) expression (B: *upper panel*, representative iNOS expression by western blot; *lower panel*, statistic analysis of western results standardized by β -actin), total nitric oxide (NO) content (C), and nitrotyrosine content (D) in CMECs. $n=8-12$ wells/group. # $p<0.05$, ## $p<0.01$ versus Control + Sham group, respectively. ** $p<0.05$ versus AGE-BSA + Sham group.

sequent Trx-1 nitritive inactivation in the setting of AGE-BSA-induced amplification of SI/R-induced CMECs injury. Finally, we have identified effective interventions capable of attenuating diabetic cardiac microvascular endothelial I/R injury.

It has been previously demonstrated that cardiac microvascular endothelial injury precedes cardiomyocyte injury in I/R situations (22). Attenuating endothelial injury can reduce cardiomyocyte cell death after ischemia and reperfusion ultimately. Patients with diabetes with acute myocardial infarction are more likely to suffer from "no reflow" after interventional therapy (20), suggesting the enhanced vulnerability of diabetic endothelial cells to I/R damage. However, the precise mechanism by which this susceptibility occurs requires elucidation. AGEs are nonenzymatically modified proteins or lipids that become glycosylated and oxidized after contact with sugars (24). AGEs form *in vivo* during aging, or in hyperglycemic environments, and are contributive to the pathophysiology of vascular disease in diabetes (2). Previous studies demonstrate that AGEs alter properties of the large

matrix proteins collagen, vitronectin, and laminin *via* formation of intermolecular AGE-AGE covalent or crosslinking bonds that destroy the extracellular structure (10, 12). AGEs can also interact with its receptor RAGE to alter intracellular endothelial function, increasing intercellular adhesion molecule-1, interleukin-6, and vascular cellular adhesion molecule-1 expression, thereby amplifying the inflammatory process (1, 16). As I/R injury is closely related to inflammation pathways; these studies indicate the possible association of AGEs to cardiac microvascular endothelial I/R injury. Presently, we demonstrated that incubation of CMECs with a pathologically relevant concentration of AGEs (34) increased cellular susceptibility to I/R injury evidenced by increased LDH release and caspase-3 activity. These results suggest that interventions which decrease AGE concentration or block AGE signaling can mitigate cardiac microvascular endothelial I/R injury in patients with diabetes.

Considerable evidence demonstrates increased oxidative stress in both patients with diabetes and animal diabetic models (8). It has been documented that AGEs, *via* binding





FIG. 4. Effects of AGE-BSA preculture on subsequent simulated ischemia/reperfusion-induced Trx-1 inactivation and nitration in CMECs. AGE-BSA further decreased already SI/R-attenuated thioredoxin (Trx) activity (**A**) and had no effect of the SI/R-induced Trx-1 expression (**B**: upper panel, representative Trx-1 expression by western blot; lower panel, statistic analysis of western results standardized by β -actin) and increased the SI/R induced the Trx-1 nitration (**C**: upper panel, representative nitrated and total Trx by immunoprecipitation; lower panel, statistic analysis of Trx nitration standardized by total Trx) in CMECs. $n=8-12$ wells/group. # $p<0.05$, ## $p<0.01$ versus Control + Sham group, * $p<0.05$, ** $p<0.01$ versus AGE-BSA + Sham group, respectively.

with RAGE, activate NADPH oxidase and increase production of ROS in endothelial cells (32). The increase of ROS induced by AGEs result in the activation of NF- κ B, followed by increased intercellular adhesion molecule-1 and vascular cellular adhesion molecule-1 expression, causing endothelial cell damage (16). Recent studies report that nitritative stress might be instrumental in the pathogenesis of diabetes (14). In patients with diabetes and animals, iNOS expression and activity is elevated (4). The increased nitric oxide produced by iNOS reacts with increased superoxide generated by NADPH oxidase, resulting in peroxynitrite overproduction, leading to

subsequent protein modification and cellular injury in diabetes (18, 29). In the present study, we demonstrated that AGE-BSA not only increased oxidative stress in CMECs (evidenced by increased superoxide anion formation) but also increased total iNOS expression, NO content, and nitrotyrosine production. These data indicate that AGEs promote SI/R injury not only by enhancing oxidative stress but also by nitritative stress. Our results revealing the beneficial effects of a peroxynitrite decomposition catalyst provided direct evidence that AGEs increase SI/R injury in CMECs *via* nitritative stress augmentation.

FIG. 5. Effects of preventing Trx-1 nitration or treatment with exogenous Trx-1 on subsequent simulated ischemia/reperfusion-induced injury and RAGE expression in AGE-BSA precultured CM ECs. EUK134 or hTrx-1 attenuates SI/R-induced LDH release (A) and caspase-3 activity (B) and nitrotyrosine content (C) and decreased the Trx nitration (D: upper panel representative nitrated and total Trx by immunoprecipitation, lower panel statistic analysis of Trx nitration standardized by total Trx.) and receptor of AGE (RAGE) expression (F: upper panel, representative RAGE expression by western blot; lower panel, statistic analysis of western results standardized by β -actin) and recovered Trx activity (E) in the cells precultured with AGE-BSA. Nty, nitrotyrosine. $n=8-12$ wells/group. $*p<0.05$, $**p<0.01$ versus SI/R + vehicle group, respectively.



Trx is a 12-kDa protein ubiquitously expressed in all living cells, performing a variety of biological functions related to cell proliferation and apoptosis (15, 38). Studies have demonstrated that in addition to upregulation or downregulation of Trx expression at the gene level, Trx activity is regulated by posttranslational modification, such as oxidation, glutathionylation, and S-nitrosylation (6, 9). Recently, it has been demonstrated that Trx can be modified at its tyrosine residue, in a process known as protein nitration, resulting in irreversible inactivation *via* a peroxy-nitrite-dependent fashion (37). Moreover, this nitrative Trx inactivation plays a key pathologic role in situations such as I/R injury in diabetes (37). In the present study, we found that AGE-BSA exacerbated Trx inactivation after SI/R without altering Trx expression. These results indicate that AGE-BSA decreases Trx activity *via* post-translational modification. Indeed, we found that AGE-BSA amplified SI/R-induced Trx nitration and that recombinant hTrx-1 supplementation effectively attenuated SI/R-induced injury.

Several different receptors for AGEs have been discovered. These include RAGE, AGE-R1 (oligosaccharyl transferase-48), AGE-R2 (80K-H phosphoprotein), AGE-R3 (galectin-3), and the class A macrophage scavenger receptor types I and II (30). Among the receptors for AGEs, RAGE is recognized to initiate the intracellular signaling disruptive of cellular function *via* recognition and binding of AGEs (5). In the present study, we found that AGE-BSA promoted nitrative stress and subsequent Trx-1 nitration in CMECs. More importantly, we demonstrated that treatment with sRAGE (a decoy of RAGE) attenuated AGE-BSA exacerbated nitrative stress and Trx nitration and decreased SI/R-induced injury. These results suggest that RAGE signaling is responsible for AGE-BSA-induced nitrative stress and Trx nitration post-SI/R. It has been shown that RAGE is upregulated when AGE ligands accumulate, resulting in positive-feedback activation (23). We also currently demonstrate that RAGE expression is decreased in the setting of nitrative stress and Trx nitration inhibition in CMECs, suggestive of a vicious cycle involving




FIG. 6. Effects of blocking RAGE on subsequent simulated ischemia/reperfusion-induced injury and Trx-1 inactivation and nitration in AGE-BSA precultured CMECs. Soluble RAGE (sRAGE) attenuates SI/R-induced LDH release (**A**) and caspase-3 activity (**B**) and Trx nitration (**C**: upper panel, representative nitrated and total Trx by immunoprecipitation; lower panel, statistic analysis of Trx nitration standardized by total Trx) and gp91phox expression by western blot; **E**: upper panel, representative gp91phox expression by western blot; lower panel, statistic analysis of western results standardized by β -actin) and recovered SI/R reduced Trx activity (**D**) in the cells precultured with AGE-BSA. Nty, nitrotyrosine. $n=8-12$ wells/group. $*p < 0.05$, $**p < 0.01$ versus SI/R + vehicle group, respectively.

AGE-RAGE signaling and Trx nitration. Experiments directed toward identification of the detailed signaling network regulating AGE-RAGE/Trx inactivation are currently ongoing.

In summary, our results demonstrated that AGEs promote I/R injury in CMECs through the RAGE/Trx nitration pathway. Blocking peroxynitrite formation and RAGE signaling by sRAGE or exogenous Trx-1 supplementation significantly protected AGE-BSA-induced CMECs from SI/R-induced injury. These results suggest that therapeutic interventions preserving Trx-1 activity in the patient with diabetes may further help in improving patient outcomes after myocardial I/R injury.

Acknowledgments

This research was supported by the following grants: National Natural Science Foundation of China 81070676 (L.T.),

National 863 Project of China 2009AA02Z104 (L.T.), and Subject Boosting Project of Xijing Hospital XJZT08Z02 (L.T.).

Author Disclosure Statement

No competing financial interests exist for any of the listed authors of this article.

References

1. Basta G, Schmidt AM, and De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. *Cardiovasc Res* 63: 582-592, 2004.
2. Brownlee M. Advanced protein glycosylation in diabetes and aging. *Annu Rev Med* 46: 223-234, 1995.
3. Brownlee M, Vlassara H, and Cerami A. Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. *Diabetes* 34: 938-941, 1985.

4. Bucciarelli LG, Ananthakrishnan R, Hwang YC, Kaneko M, Song F, Sell DR, Strauch C, Monnier VM, Yan SF, Schmidt AM, and Ramasamy R. RAGE and modulation of ischemic injury in the diabetic myocardium. *Diabetes* 57: 1941–1951, 2008.
5. Bucciarelli LG, Wendt T, Rong L, Lalla E, Hofmann MA, Goova MT, Taguchi A, Yan SF, Yan SD, Stern DM, and Schmidt AM. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. *Cell Mol Life Sci* 59: 1117–1128, 2002.
6. Casagrande S, Bonetto V, Fratelli M, Gianazza E, Eberini I, Massignan T, Salmona M, Chang G, Holmgren A, and Ghezzi P. Glutathionylation of human thioredoxin: a possible crosstalk between the glutathione and thioredoxin systems. *Proc Natl Acad Sci U S A* 99: 9745–9749, 2002.
7. Coughlan MT, Thorburn DR, Penfold SA, Laskowski A, Harcourt BE, Sourris KC, Tan AL, Fukami K, Thallas-Bonke V, Nawroth PP, Brownlee M, Bierhaus A, Cooper ME, and Forbes JM. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. *J Am Soc Nephrol* 20: 742–752, 2009.
8. Forbes JM, Coughlan MT, and Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. *Diabetes* 57: 1446–1454, 2008.
9. Haendeler J, Hoffmann J, Tischler V, Berk BC, Zeiher AM, and Dimmeler S. Redox regulatory and anti-apoptotic functions of thioredoxin depend on S-nitrosylation at cysteine 69. *Nat Cell Biol* 4: 743–749, 2002.
10. Hammes HP, Weiss A, Hess S, Araki N, Horiuchi S, Brownlee M, and Preissner KT. Modification of vitronectin by advanced glycation alters functional properties *in vitro* and in the diabetic retina. *Lab Invest* 75: 325–338, 1996.
11. Holmgren A and Bjornstedt M. Thioredoxin and thioredoxin reductase. *Methods Enzymol* 252: 199–208, 1995.
12. Howard EW, Benton R, Ahern-Moore J, and Tomasek JJ. Cellular contraction of collagen lattices is inhibited by non-enzymatic glycation. *Exp Cell Res* 228: 132–137, 1996.
13. King H, Aubert RE, and Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. *Diabetes Care* 21: 1414–1431, 1998.
14. Kowluru RA. Effect of reinstatement of good glycemic control on retinal oxidative stress and nitrate stress in diabetic rats. *Diabetes* 52: 818–823, 2003.
15. Lincoln DT, Ali Emadi EM, Tonissen KF, and Clarke FM. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. *Anticancer Res* 23: 2425–2433, 2003.
16. Neumann A, Schinzel R, Palm D, Riederer P, and Munch G. High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-kappaB activation and cytokine expression. *FEBS Lett* 453: 283–287, 1999.
17. Nishida M, Carley WW, Gerritsen ME, Ellingsen O, Kelly RA, and Smith TW. Isolation and characterization of human and rat cardiac microvascular endothelial cells. *Am J Physiol* 264: H639–H652, 1993.
18. Ren XY, Li YN, Qi JS, and Niu T. Peroxynitrite-induced protein nitration contributes to liver mitochondrial damage in diabetic rats. *J Diabetes Complications* 22: 357–364, 2008.
19. Rojas A, Mercadal E, Figueroa H, and Morales MA. Advanced glycation and ROS: a link between diabetes and heart failure. *Curr Vasc Pharmacol* 6: 44–51, 2008.
20. Romano M, Buffoli F, Tomasi L, Aroldi M, Lettieri C, Ferrari MR, and Zanini R. The no-reflow phenomenon in acute myocardial infarction after primary angioplasty: incidence, predictive factors, and long-term outcomes. *J Cardiovasc Med (Hagerstown)* 9: 59–63, 2008.
21. Sangiorgi G, Romagnoli E, Biondi-Zoccai G, Margheri M, Tamburino C, Barbagallo R, Falchetti E, Vittori G, Agostoni P, Cosgrave J, and Colombo A. Percutaneous coronary implantation of sirolimus-eluting stents in unselected patients and lesions: clinical results and multiple outcome predictors. *Am Heart J* 156: 871–878, 2008.
22. Scarabelli T, Stephanou A, Rayment N, Pasini E, Comini L, Curello S, Ferrari R, Knight R, and Latchman D. Apoptosis of endothelial cells precedes myocyte cell apoptosis in ischemia/reperfusion injury. *Circulation* 104: 253–256, 2001.
23. Schmidt AM and Stern DM. RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. *Trends Endocrinol Metab* 11: 368–375, 2000.
24. Singh R, Barden A, Mori T, and Beilin L. Advanced glycation end-products: a review. *Diabetologia* 44: 129–146, 2001.
25. Tao L, Gao E, Bryan NS, Qu Y, Liu HR, Hu A, Christopher TA, Lopez BL, Yodoi J, Koch WJ, Feelisch M, and Ma XL. Cardioprotective effects of thioredoxin in myocardial ischemia and reperfusion: role of S-nitrosation [corrected]. *Proc Natl Acad Sci U S A* 101: 11471–11476, 2004.
26. Tao L, Gao E, Hu A, Coletti C, Wang Y, Christopher TA, Lopez BL, Koch W, and Ma XL. Thioredoxin reduces post-ischemic myocardial apoptosis by reducing oxidative/nitrate stress. *Br J Pharmacol* 149: 311–318, 2006.
27. Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, Lopez BL, Koch W, Chan L, Goldstein BJ, and Ma XL. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrate stress. *Circulation* 115: 1408–1416, 2007.
28. Tao L, Jiao X, Gao E, Lau WB, Yuan Y, Lopez B, Christopher T, Ramachandra Rao SP, Williams W, Southan G, Sharma K, Koch W, and Ma XL. Nitrate inactivation of thioredoxin-1 and its role in posts ischemic myocardial apoptosis. *Circulation* 114: 1395–1402, 2006.
29. Vareniuk I, Pavlov IA, and Obrosova IG. Inducible nitric oxide synthase gene deficiency counteracts multiple manifestations of peripheral neuropathy in a streptozotocin-induced mouse model of diabetes. *Diabetologia* 51: 2126–2133, 2008.
30. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. *Diabetes Metab Res Rev* 17: 436–443, 2001.
31. Wang XL, Liu HR, Tao L, Liang F, Yan L, Zhao RR, Lopez BL, Christopher TA, and Ma XL. Role of iNOS-derived reactive nitrogen species and resultant nitrate stress in leukocytes-induced cardiomyocyte apoptosis after myocardial ischemia/reperfusion. *Apoptosis* 12: 1209–1217, 2007.
32. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, and Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. *Am J Physiol Endocrinol Metab* 280: E685–E694, 2001.
33. Wei L, Sun D, Yin Z, Yuan Y, Hwang A, Zhang Y, Si R, Zhang R, Guo W, Cao F, and Wang H. A PKC-beta inhibitor protects against cardiac microvascular ischemia reperfusion injury in diabetic rats. *Apoptosis* 15: 488–498, 2010.
34. Xu B, Chibber R, Ruggiero D, Kohner E, Ritter J, and Ferro A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. *FASEB J* 17: 1289–1291, 2003.
35. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, and Makita Z. Advanced glycation end

- product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. *J Biol Chem* 277: 20309–20315, 2002.
36. Yang D, Guo S, Zhang T, and Li H. Hypothermia attenuates ischemia/reperfusion-induced endothelial cell apoptosis via alterations in apoptotic pathways and JNK signaling. *FEBS Lett* 583: 2500–2506, 2009.
37. Yin T, Hou R, Liu S, Lau WB, Wang H, and Tao L. Nitrate inactivation of thioredoxin-1 increases vulnerability of diabetic hearts to ischemia/reperfusion injury. *J Mol Cell Cardiol* 49: 354–361, 2010.
38. Yoshida T, Oka S, Masutani H, Nakamura H, and Yodoi J. The role of thioredoxin in the aging process: involvement of oxidative stress. *Antioxid Redox Signal* 5: 563–570, 2003.

Address correspondence to:

Dr. Ling Tao
 Department of Cardiology
 Xijing Hospital
 The Fourth Military Medical University
 15 Changle West Road
 Xi'an 710032
 China

E-mail: lingtao2006@gmail.com

Dr. Haichang Wang
 Department of Cardiology
 Xijing Hospital
 The Fourth Military Medical University
 15 Changle West Road
 Xi'an 710032
 China

E-mail: wanghc@fmmu.edu.cn

Date of first submission to ARS Central, November 15, 2010;
 date of acceptance, December 2, 2010.

Abbreviations Used

AGEs = advanced glycation end products
 BSA = bovine serum albumin
 CMECs = cardiac microvascular endothelial cells
 DMEM = Dulbecco's minimum essential medium
 I/R = ischemia/reperfusion
 LDH = lactate dehydrogenase
 NO = nitric oxide
 PBS = phosphate-buffered saline
 RAGE = receptor of advanced end product
 ROS = reactive oxygen species
 SI/R = simulated ischemia/reperfusion
 sRAGE = soluble receptor of advanced end product
 Trx = thioredoxin

This article has been cited by:

1. Nilanjana Maulik , Juan A. Sanchez . 2011. Risk Factors in Heart Disease: Therapeutic Interventions. *Antioxidants & Redox Signaling* **15**:7, 1765-1767. [[Citation](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]